Contents
Contents
The difference between Medicare improper payments and fraud losses starts with what the Centers for Medicare & Medicaid Services measures: compliance with payment requirements. That includes overpayments, underpayments and payments with too little documentation to establish whether they were proper. Knowingly submitting false claims to get Medicare money is the conduct a whistleblower case can expose. For someone in billing, clinical review or pharmacy operations, the useful question is what happened behind the finding. Which record was missing? What did the business bill? Who knew the claim had a problem, and what happened to the money?
The agency describes the measure in its FY2025 improper-payments fact sheet. We follow the particular claims, payment decisions and people behind a finding. That is where your knowledge of the healthcare business matters.
The Medicare CERT error rate estimates the share of fee-for-service payments that fail Medicare’s payment requirements. CMS uses Comprehensive Error Rate Testing to review sampled claims and project the results across the payment population.
For FY2025, Medicare reported a 6.55% improper-payment rate, representing $28.83 billion, against an expenditure base of $439.88 billion. Those figures concern claims submitted from July 1, 2023, through June 30, 2024.
The fee-for-service technical report explains how the estimate is built. CERT groups claims by service or bill type, reviews the sample and applies sampling weights and expenditure amounts. Contractor groups contribute to the national result according to their share of expenditures.
The Medicare improper payment confidence interval makes the sampling uncertainty visible. The report gives a 95% interval of 5.9% to 7.2% for the national rate. The estimate has a range because the agency reviewed a sample of the payment population.
Documentation problems account for the largest share of estimated fee-for-service improper payments. The review also identifies medical necessity, incorrect coding and other errors. Each category describes what the review found wrong with support for the payment.
In the adjusted FY2025 fee-for-service breakdown, insufficient documentation accounts for 53.0% of estimated improper payments, and no documentation accounts for 12.0%. These are shares of the estimated improper dollars. No documentation. We think a paid claim deserves a better explanation.
Unsupported documentation and payment errors meet at a practical question: can the provider’s records support what Medicare paid? A missing order, inadequate clinical support and an incorrect code can each leave the reviewer with a different problem to resolve.
The category tells an insider where the review stopped. The underlying records explain how the claim got there.
A billing employee may recognize an instruction to keep using a disputed code. A clinician may recognize a later version of a note. A reviewer may know that the same concern reached management before the next claim went out. Those connections give the payment finding a history inside the business.
The technical report also says that fraud can remain undetected among payments classified as correct by CERT. An insider who knows that a supporting record was changed brings information that a payment-accuracy classification can miss.
CERT’s hospital categories follow billing arrangements as well as service settings. Its category called Part A excluding the hospital inpatient prospective payment system includes institutional claims that may contain services paid under Part B. The claim form and type of bill determine the grouping. A hospital’s institutional submission can therefore appear under that Part A label even when the service draws payment from Part B.
The report also adjusts for inpatient claims denied under Part A that could be rebilled under Part B. The agency reprices services in a random subsample to account for that payment possibility. For FY2025, the adjustment lowered the overall rate by 0.20 percentage points, from an unadjusted 6.75% to the published rate. That is a payment-setting distinction a hospital billing employee would recognize: the care, the inpatient bill and the amount payable through another route each have their own place in the calculation.
Gross improper payments add overpayments and the absolute amount of underpayments. Net improper payments subtract underpayments from overpayments. Gross measures payment error in both directions. Net measures the balance after the directions offset.
For fee-for-service, the adjusted FY2025 table displays $27.9 billion in overpayments and $1.0 billion in underpayments. Underpayment means the program paid less than the amount due. It still contributes to the gross error measure because the payment was wrong.
This is why the word gross does real work. A headline about money lost can quietly turn an amount Medicare should have paid into an amount supposedly taken from it. We think the direction of the money deserves more attention than that.
The Part D improper payment estimate population for FY2025 reporting concerns calendar-year 2023 payments, with a $105.56 billion denominator. The measurement follows prescription-drug payment data and supporting documentation through a separate review from FFS.
The agency’s Part D technical results report gross improper payments of $4.23 billion, or 4.00%, and net improper payments of $3.18 billion, or 3.01%. The components are $3.70 billion in overpayments and $0.52 billion in underpayments. The Part D gross estimate’s 95% confidence interval runs from 3.57% to 4.46%, or $3.77 billion to $4.71 billion.
The agency compares the prescribed drug, the drug dispensed and the sponsor’s prescription drug event record. A discrepancy can change the recorded gross drug cost. A corrected cost below the amount on the event record produces an overpayment error. A corrected cost above it produces an underpayment error.
Gross drug cost combines plan and beneficiary liability for the drug, including the relevant dispensing and other charges. Federal subsidies pay portions of those liabilities. That makes a pharmacy transaction, a sponsor’s drug-event submission and CMS’s payment calculation distinct stages in the same payment chain.
For someone in pharmacy or plan operations, the connection is concrete. The prescription identifies what was ordered. The dispensing record identifies what went to the patient. The event record carries the reported drug and cost information. A mismatch becomes meaningful when those records are connected to the payment affected by it.
Missing or invalid documentation accounted for 75.00% of errors found in the FY2025 Part D audit sample. Drug discrepancies accounted for 7.14%, and pricing discrepancies for 17.86%. The denominator here is errors found in the sample.
The fee-for-service breakdown measures estimated improper dollars. The Part D breakdown counts errors found in the sample. Those denominators matter when a plan employee weighs a documentation finding against the money affected by it.
The operational distinction matters too. Documentation review asks whether the plan can support a claim. Drug review compares the prescription with what was dispensed. Pricing review compares the corresponding costs. A plan employee who knows why the event data differs from the pharmacy record can explain what a category label leaves out.
Medicare improper payment historical methodology changes affect what a trend line means. The fee-for-service series reported net error from FY1996 through FY2003 and gross error from FY2004 onward. The treatment of underpayments changed, so the earlier and later rates use different definitions.
For FY2009, Medicare initially published a 7.8% fee-for-service error rate. The later historical series reports 12.4% for that same year. In its November 2009 explanation, the agency described stricter documentation review, including ending the use of prior billing history to fill gaps in treatment records and requiring clinical support for durable medical equipment claims.
The Congressional Research Service’s 2011 report, Medicare Program Integrity: Activities to Protect Medicare from Payment Errors, Fraud, and Abuse, also describes the transfer of inpatient hospital error measurement to CERT from the organizations that previously conducted it. The revised rate reflected changed review standards and methods.
Part D has its own breaks. The Department of Health and Human Services changed the methodology for FY2023, and FY2024 established a new baseline. For FY2025, the agency moved from cohort sampling to random beneficiary selection and said that change preserved the baseline. Ignoring those changes can make a change in measurement look like a change in conduct.
CERT estimates national fee-for-service payment error. Recovery Audit Contractors review payments to identify overpayments and underpayments. Unified Program Integrity Contractors investigate leads through claims analysis, interviews, site visits and medical review, and make referrals to law enforcement. These jobs connect, but each produces a different kind of result.
The Centers for Medicare & Medicaid Services describes those contractor roles in its program-integrity report to Congress. A targeted review follows a particular provider or billing concern. CERT uses a national sampling design. The concentration of errors in a targeted review therefore answers a question about that review’s selected claims.
The same distinction follows the money. Preventing a payment stops money going out. Recovering a payment brings money back. A settlement states an obligation to pay. The collection record shows what arrived.
An insider can connect the error finding to the original record, the submitted claim, the warning and the payment. Our work on Medicare fraud evidence follows those connections through the business.
In fee-for-service, the 835 remittance advice records how the claim was processed, including adjustments and responsibility codes. The funds-transfer record shows the money transferred. Provider-level offsets can change the deposit from the amounts shown for the current claims. For a finance employee, those records can explain how a questioned bill became money in the account.
In Part D, the pharmacy claim, the sponsor’s drug-event data, rebate reporting and Medicare reconciliation are separate records or calculations. Following that chain shows how the pharmacy information affected federal payment.
The business’s response also matters. The original documentation, later revisions, dated billing concerns and subsequent claims can show who understood the problem and what continued afterward. We work with your knowledge of the operation to connect the payment issue to those decisions. That is where an audit category can lead to an account of what the business actually did. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
A Medicare fraud loss total requires evidence identifying fraudulent payments and the resulting loss. Putting the fee-for-service, Part C and Part D gross estimates together combines different underlying periods and methods. We follow the claim and the money because that is where an insider’s account can explain the conduct behind a payment.
For FY2025, the agency reported a Medicare Advantage Part C improper-payment rate of 6.09%, or $23.67 billion, using payment year 2023. Most Part C improper payments involved supporting documentation that failed to substantiate diagnosis data submitted for payment. The distinctions between programs and payment systems matter when an employee follows a claim through more than one payer.
If you know how unsupported billing, altered records or ignored payment warnings continued bringing Medicare money into a business, speak with our whistleblower experts about what happened behind the finding. We work beside you to build the case around the claims, the money and the decisions you witnessed, and bring in Medicare fraud whistleblower lawyers who understand the payment system involved. Your knowledge of the health care operation gives us a place to begin, and we stay with you through the case.